Other equities research analysts have also recently issued research reports about the company. Numis Securities Ltd reaffirmed an add rating and set a GBX 870 ($11.12) target price on shares of Abcam Plc in a research report on Tuesday, January 10th. Peel Hunt reaffirmed a hold rating and set a GBX 750 ($9.59) target price on shares of Abcam Plc in a research report on Monday, March 6th. Stifel Nicolaus reaffirmed a hold rating and set a GBX 890 ($11.38) target price on shares of Abcam Plc in a research report on Tuesday, April 4th. Finally, JPMorgan Chase & Co. upped their target price on Abcam Plc from GBX 678 ($8.67) to GBX 864 ($11.05) and gave the stock a neutral rating in a research report on Monday, March 27th. One research analyst has rated the stock with a sell rating and four have given a hold rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of GBX 819.20 ($10.47).
Abcam Plc (LON:ABC) opened at 839.24 on Thursday. The company has a 50-day moving average of GBX 851.51 and a 200 day moving average of GBX 835.68. Abcam Plc has a 12-month low of GBX 587.00 and a 12-month high of GBX 948.00. The stock’s market cap is GBX 1.70 billion.
The business also recently announced a dividend, which was paid on Thursday, April 13th. Shareholders of record on Thursday, March 16th were given a dividend of GBX 2.83 ($0.04) per share. The ex-dividend date was Thursday, March 16th. This represents a yield of 0.31%.
In related news, insider Alan Thomas Hirzel bought 6,000 shares of the firm’s stock in a transaction on Monday, March 20th. The stock was purchased at an average price of GBX 839 ($10.73) per share, with a total value of £50,340 ($64,356.94).
About Abcam Plc
Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/abcam-plcs-abc-sell-rating-reiterated-at-panmure-gordon-2/1762539.html
Receive News & Ratings for Abcam Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam Plc and related companies with MarketBeat.com's FREE daily email newsletter.